Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEICAM 9906: FEC vs FEC + Paclitaxel in Node-Positive Breast Cancer
NCT00129922Phase 3Completed
- Sponsor
- GEICAM
- Start
- Nov 1999
- Primary completion
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel in breast cancer (2 arms), sponsored by GEICAM. Primary endpoint: Disease-Free Survival at 5 years. Started Nov 1999; status: completed.
02
Drugs
paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00129922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00129922.